The Immunologic Effects of HCV Therapy With Fixed Dose Combination Ledipasvir/Sofosbuvir (HARVONI) in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 23 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 23 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.